Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments

Gandhi, Maher K. and Khanna, Rajiv (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infectious Diseases, 4 12: 725-738. doi:10.1016/S1473-3099(04)01202-2


Author Gandhi, Maher K.
Khanna, Rajiv
Title Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments
Journal name Lancet Infectious Diseases   Check publisher's open access policy
ISSN 1473-3099
Publication date 2004-12-01
Year available 2004
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/S1473-3099(04)01202-2
Open Access Status Not yet assessed
Volume 4
Issue 12
Start page 725
End page 738
Total pages 14
Editor J. McConnell
Place of publication London, U.K.
Publisher The Lancet Publishing Group
Language eng
Subject C1
110704 Cellular Immunology
110309 Infectious Diseases
Abstract After initial infection, human cytomegalovirus remains in a persistent state with the host. Immunity against the virus controls replication, although intermitent viral shedding can still take place in the seropositive immunocompetent person. Replication of cytomegalovirus in the absence of an effective immune response is central to the pathogenesis of disease. Therefore, complications are primarily seen in individuals whose immune system is immature, or is suppressed by drug treatment or coinfection with other pathogens. Although our increasing knowledge of the host-virus relationship has lead to the development of new pharmacological strategies for cytomegalovirus-associated infections, these strategies all have limitations-eg, drug toxicities, development of resistance, poor oral bioavailability, and low potency. Immune-based therapies to complement pharmacological strategies for the successful treatment of virus-associated complications should be prospectively investigated.
Keyword Infectious Diseases
Stem-cell Transplantation
Allogeneic Bone-marrow
Cytotoxic T-lymphocytes
Active Antiretroviral Therapy
Solid-organ Transplantation
Polymerase-chain-reaction
Cmv-seropositive Recipients
Replace Preemptive Therapy
Open-label Trial
Glycoprotein-b
Q-Index Code C1
Grant ID 1 R21 CA106172-01A1
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Excellence in Research Australia (ERA) - Collection
2005 Higher Education Research Data Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 294 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 331 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 13:24:54 EST